NVAX Quote, Financials, Valuation and Earnings

Denali Therapeutics, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of --. Novavax, Inc.'s return on equity of -- beat Denali Therapeutics, Inc.'s return on equity of -44.34%.

Novavax, Inc. has a consensus price target of $12.78, signalling upside risk potential of 84.12%. On the other hand Denali Therapeutics, Inc. has an analysts' consensus of $32.21 which suggests that it could grow by 89.61%. Given that Denali Therapeutics, Inc. has higher upside potential than Novavax, Inc., analysts believe Denali Therapeutics, Inc. is more attractive than Novavax, Inc..

Novavax, Inc. has a beta of 2.305, which suggesting that the stock is 130.478% more volatile than S&P 500. In comparison Denali Therapeutics, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.475%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Denali Therapeutics, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are larger than Denali Therapeutics, Inc. quarterly revenues of --. Novavax, Inc.'s net income of -$202.4M is lower than Denali Therapeutics, Inc.'s net income of -$126.9M. Notably, Novavax, Inc.'s price-to-earnings ratio is 3.92x while Denali Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.10x versus 6.62x for Denali Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of 33.68%. Novavax, Inc.'s return on equity of -- beat Merck & Co., Inc.'s return on equity of 39.63%.

Novavax, Inc. has a consensus price target of $12.78, signalling upside risk potential of 84.12%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that Novavax, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Novavax, Inc. is more attractive than Merck & Co., Inc..

Novavax, Inc. has a beta of 2.305, which suggesting that the stock is 130.478% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. Novavax, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Novavax, Inc.'s net income of -$202.4M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Novavax, Inc.'s price-to-earnings ratio is 3.92x while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.10x versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of -19.69%. Novavax, Inc.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

Novavax, Inc. has a consensus price target of $12.78, signalling upside risk potential of 84.12%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Novavax, Inc. has higher upside potential than Moderna, Inc., analysts believe Novavax, Inc. is more attractive than Moderna, Inc..

Novavax, Inc. has a beta of 2.305, which suggesting that the stock is 130.478% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Novavax, Inc.'s net income of -$202.4M is lower than Moderna, Inc.'s net income of -$200M. Notably, Novavax, Inc.'s price-to-earnings ratio is 3.92x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.10x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -287.29% compared to Novavax, Inc.'s net margin of 21.32%. Novavax, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.

Novavax, Inc. has a consensus price target of $12.78, signalling upside risk potential of 84.12%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Novavax, Inc. has higher upside potential than Pfizer Inc., analysts believe Novavax, Inc. is more attractive than Pfizer Inc..

Novavax, Inc. has a beta of 2.305, which suggesting that the stock is 130.478% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Novavax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Novavax, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Novavax, Inc. quarterly revenues are $70.4M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Novavax, Inc.'s net income of -$202.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Novavax, Inc.'s price-to-earnings ratio is 3.92x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax, Inc. is 1.10x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.